Urinary pentosidine and plasma homocysteine levels at baseline predict future fractures in osteoporosis patients under bisphosphonate treatment.
To clarify what kind of risk factors predict incident fractures in patients treated with bisphosphonates, the authors investigated the relationship between baseline characteristics and incident vertebral fracture in Japanese osteoporosis patients undergoing bisphosphonate treatment. This was a multi-center follow-up study conducted at three centers, in which a total of 251 Japanese patients with osteoporosis (mean age 70.5 years) from the three centers were followed for 3.2 ± 2.0 years. Baseline data, including pre-existing fractures, bone mineral density in the lumbar spine (LBMD), bone metabolic markers, urinary pentosidine, and plasma homocysteine, were evaluated. Changes in LBMD, bone turnover markers, and incident fractures after the treatment were followed. Sixty-one patients developed incident vertebral fractures; this group of patients was older and had lower LBMD, a higher prevalent vertebral fracture number, and higher homocysteine and pentosidine levels than patients who did not develop incident vertebral fractures. Changes in LBMD, urinary N-terminal telopeptides of type I collagen (NTX), and bone-derived alkaline phosphatase showed no significant association with the occurrence of vertebral fractures. Cox's proportional hazard model demonstrated that age, prevalent fracture, pentosidine, and homocysteine were independent predictors of the incident vertebral fracture rate under bisphosphonate treatment. Higher baseline levels of pentosidine and homocysteine in osteoporosis patients are potential risk factors for incident vertebral fractures when these patients are treated with bisphosphonates. Further clarification is needed to explain why such patients have higher fracture susceptibility.
Shiraki
Masataka
M
Research Institute and Practice for Involutional Diseases, Nagano, Japan.
Kuroda
Tatsuhiko
T
Shiraki
Yumiko
Y
Tanaka
Shiro
S
Higuchi
Tsuyoshi
T
Saito
Mitsuru
M
D000368:Aged; D001120:Arginine / Q000031:analogs & derivatives* / Q000652:urine; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D005260:Female; D050723:Fractures, Bone / Q000097:blood / Q000517:prevention & control / Q000652:urine; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D008239:Lysine / Q000031:analogs & derivatives* / Q000652:urine; D008875:Middle Aged; D010024:Osteoporosis / Q000097:blood* / Q000188:drug therapy / Q000652:urine*; D016016:Proportional Hazards Models
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D006710:Homocysteine; D001120:Arginine; C062187:pentosidine; D008239:Lysine
Calcif Tissue Int. 2006 Sep;79(3):160-8
16969591
Bone. 2000 Nov;27(5):687-94
11062357
J Bone Miner Res. 2003 Jun;18(6):1051-6
12817758
J Clin Endocrinol Metab. 1994 Dec;79(6):1693-700
7989477
Osteoporos Int. 2010 Apr;21(4):655-66
19484165
Bone. 2004 Apr;34(4):599-604
15050889
Ann N Y Acad Sci. 2005 Jun;1043:710-7
16037297
J Clin Endocrinol Metab. 2008 Mar;93(3):1013-9
18160470
Lancet. 1996 Dec 7;348(9041):1535-41
8950879
J Bone Miner Res. 2004 Feb;19(2):323-9
14969403
N Engl J Med. 2004 May 13;350(20):2042-9
15141042
Osteoporos Int. 2010 Feb;21(2):243-50
19421701
Am J Med. 2002 Mar;112(4):281-9
11893367
Osteoporos Int. 2010 Feb;21(2):195-214
19760059
J Bone Miner Res. 1997 Sep;12(9):1438-45
9286760
Biol Pharm Bull. 1998 Oct;21(10):1005-8
9821800
N Engl J Med. 2001 May 10;344(19):1434-41
11346808
J Bone Miner Metab. 2001;19(6):331-7
11685647
JAMA. 1999 Aug 18;282(7):637-45
10517716
Eur J Clin Chem Clin Biochem. 1991 Sep;29(9):549-54
1760484
Osteoporos Int. 2009 Jun;20(6):887-94
18850239
J Bone Miner Metab. 2008;26(6):595-602
18979159
Arthritis Rheum. 2001 Nov;44(11):2611-9
11710717
Bone. 2009 Dec;45(6):1053-8
19679211
J Bone Miner Res. 1996 Jul;11(7):984-96
8797120
JAMA. 1999 Oct 13;282(14):1344-52
10527181
N Engl J Med. 2004 May 13;350(20):2033-41
15141041
Osteoporos Int. 2006;17(7):986-95
16552468
BMJ. 2009 Jun 23;338:b2266
19549996
Bone. 2002 Jul;31(1):1-7
12110404
Curr Osteoporos Rep. 2007 Jun;5(2):62-6
17521507
Osteoporos Int. 2008 Sep;19(9):1343-54
18373056
J Bone Miner Metab. 2008;26(1):93-100
18095070
JAMA. 2001 Feb 14;285(6):785-95
11176917
JAMA. 1998 Dec 23-30;280(24):2077-82
9875874
Bone. 2006 Mar;38(3):300-9
16271523
N Engl J Med. 2007 Nov 1;357(18):1799-809
17878149
J Clin Endocrinol Metab. 2009 Jul;94(7):2380-6
19383780
J Bone Miner Metab. 2006;24(3):219-25
16622735